Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast?

de Moraes Schenka NG, Schenka AA, de Souza Queiroz L, de Almeida Matsura M, Alvarenga M, Vassallo J.

Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):71-7.

PMID:
16540734
2.
3.

[P63 protein in the diagnosis of breast tubular carcinoma].

Noël JC, Fayt I, Fernandez-Aguilar S.

Ann Pathol. 2004 Sep;24(4):319-23. French.

PMID:
15567947
4.

Use of p63 and CD10 in the differential diagnosis of papillary neoplasms of the breast.

de Moraes Schenka NG, Schenka AA, de Souza Queiroz L, de Almeida Matsura M, Vassallo J, Alvarenga M.

Breast J. 2008 Jan-Feb;14(1):68-75. Epub 2007 Dec 11.

PMID:
18086274
5.

p63 expression in benign and malignant breast lesions.

Stefanou D, Batistatou A, Nonni A, Arkoumani E, Agnantis NJ.

Histol Histopathol. 2004 Apr;19(2):465-71. doi: 10.14670/HH-19.465.

PMID:
15024707
6.
7.

p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast.

Barbareschi M, Pecciarini L, Cangi MG, Macrì E, Rizzo A, Viale G, Doglioni C.

Am J Surg Pathol. 2001 Aug;25(8):1054-60.

PMID:
11474290
8.

Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast: an analysis of 82 samples.

Reis-Filho JS, Milanezi F, Amendoeira I, Albergaria A, Schmitt FC.

Cancer. 2003 Jun 25;99(3):172-9.

9.

The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.

Tse GM, Tan PH, Lui PC, Gilks CB, Poon CS, Ma TK, Law BK, Lam WW.

J Clin Pathol. 2007 Mar;60(3):315-20. Epub 2006 May 12.

10.

Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast.

Hilson JB, Schnitt SJ, Collins LC.

Am J Surg Pathol. 2010 Jun;34(6):896-900. doi: 10.1097/PAS.0b013e3181dd60d3.

PMID:
20463570
11.

Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections.

Moritani S, Kushima R, Sugihara H, Bamba M, Kobayashi TK, Hattori T.

Mod Pathol. 2002 Apr;15(4):397-405.

12.

Myoepithelial cell cocktail (p63+SMA) for the evaluation of sclerosing breast lesions.

Pavlakis K, Zoubouli C, Liakakos T, Messini I, Keramopoullos A, Athanassiadou S, Kafousi M, Stathopoulos EN.

Breast. 2006 Dec;15(6):705-12. Epub 2005 Dec 27.

PMID:
16384708
13.
14.
15.

The role of immunocytochemical markers in the differential diagnosis of proliferative and neoplastic lesions of the breast.

Joshi MG, Lee AK, Pedersen CA, Schnitt S, Camus MG, Hughes KS.

Mod Pathol. 1996 Jan;9(1):57-62.

PMID:
8821958
16.

Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast.

Reis-Filho JS, Milanezi F, Paredes J, Silva P, Pereira EM, Maeda SA, de Carvalho LV, Schmitt FC.

Appl Immunohistochem Mol Morphol. 2003 Mar;11(1):1-8.

PMID:
12610349
17.

A Comparative Study of Immunohistochemical Myoepithelial Cell Markers in Cutaneous Benign Cystic Apocrine Lesions.

Wood A, Houghton SL, Biswas A.

Am J Dermatopathol. 2016 Jul;38(7):475-83. doi: 10.1097/DAD.0000000000000431.

PMID:
26630681
18.
19.

Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast?

Ribeiro-Silva A, Zamzelli Ramalho LN, Garcia SB, Zucoloto S.

Pathol Oncol Res. 2003;9(1):20-3. Epub 2003 Apr 18.

20.

Mammary analog secretory carcinoma of salivary glands: a report of 2 cases with expression of basal/myoepithelial markers (calponin, CD10 and p63 protein).

Laco J, Švajdler M Jr, Andrejs J, Hrubala D, Hácová M, Vaněček T, Skálová A, Ryška A.

Pathol Res Pract. 2013 Mar;209(3):167-72. doi: 10.1016/j.prp.2012.12.005. Epub 2013 Jan 26.

PMID:
23357688

Supplemental Content

Support Center